KR102457504B1 - 암에 대한 면역요법에서의 사용을 위하여 형질주입된 t 세포 및 t 세포 수용체 - Google Patents

암에 대한 면역요법에서의 사용을 위하여 형질주입된 t 세포 및 t 세포 수용체 Download PDF

Info

Publication number
KR102457504B1
KR102457504B1 KR1020217015786A KR20217015786A KR102457504B1 KR 102457504 B1 KR102457504 B1 KR 102457504B1 KR 1020217015786 A KR1020217015786 A KR 1020217015786A KR 20217015786 A KR20217015786 A KR 20217015786A KR 102457504 B1 KR102457504 B1 KR 102457504B1
Authority
KR
South Korea
Prior art keywords
tcr
leu
ser
val
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020217015786A
Other languages
English (en)
Korean (ko)
Other versions
KR20210063486A (ko
Inventor
레오니 알텐
도미니크 마우러
세바스티안 붕크
Original Assignee
이매틱스 바이오테크놀로지스 게엠베하
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 이매틱스 바이오테크놀로지스 게엠베하 filed Critical 이매틱스 바이오테크놀로지스 게엠베하
Publication of KR20210063486A publication Critical patent/KR20210063486A/ko
Application granted granted Critical
Publication of KR102457504B1 publication Critical patent/KR102457504B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4267—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K40/4268—MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4267—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K40/4269—NY-ESO
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells
    • C12N5/163—Animal cells one of the fusion partners being a B or a T lymphocyte
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/55—Lung
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/57—Skin; melanoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
KR1020217015786A 2016-03-16 2017-03-16 암에 대한 면역요법에서의 사용을 위하여 형질주입된 t 세포 및 t 세포 수용체 Active KR102457504B1 (ko)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201662308975P 2016-03-16 2016-03-16
US62/308,975 2016-03-16
GB1604492.7 2016-03-16
GBGB1604492.7A GB201604492D0 (en) 2016-03-16 2016-03-16 Transfected t-cells and t-cell receptors for use in immunotherapy against cancers
PCT/EP2017/056260 WO2017158103A1 (en) 2016-03-16 2017-03-16 Transfected t-cells and t-cell receptors for use in immunotherapy against cancers
KR1020187029016A KR102259109B1 (ko) 2016-03-16 2017-03-16 암에 대한 면역요법에서의 사용을 위하여 형질주입된 t 세포 및 t 세포 수용체

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020187029016A Division KR102259109B1 (ko) 2016-03-16 2017-03-16 암에 대한 면역요법에서의 사용을 위하여 형질주입된 t 세포 및 t 세포 수용체

Publications (2)

Publication Number Publication Date
KR20210063486A KR20210063486A (ko) 2021-06-01
KR102457504B1 true KR102457504B1 (ko) 2022-10-20

Family

ID=55952417

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020217015786A Active KR102457504B1 (ko) 2016-03-16 2017-03-16 암에 대한 면역요법에서의 사용을 위하여 형질주입된 t 세포 및 t 세포 수용체
KR1020187029016A Active KR102259109B1 (ko) 2016-03-16 2017-03-16 암에 대한 면역요법에서의 사용을 위하여 형질주입된 t 세포 및 t 세포 수용체

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020187029016A Active KR102259109B1 (ko) 2016-03-16 2017-03-16 암에 대한 면역요법에서의 사용을 위하여 형질주입된 t 세포 및 t 세포 수용체

Country Status (16)

Country Link
US (1) US10538573B2 (enExample)
EP (1) EP3430030B1 (enExample)
JP (1) JP7340127B2 (enExample)
KR (2) KR102457504B1 (enExample)
CN (1) CN108884136B (enExample)
AU (2) AU2017235467B2 (enExample)
CA (1) CA3017502A1 (enExample)
CR (1) CR20180492A (enExample)
EA (1) EA201892021A1 (enExample)
GB (1) GB201604492D0 (enExample)
MA (2) MA43330B1 (enExample)
MX (1) MX2018011225A (enExample)
MY (1) MY189042A (enExample)
SG (1) SG11201807868VA (enExample)
TW (1) TWI764886B (enExample)
WO (1) WO2017158103A1 (enExample)

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201600853UA (en) 2013-08-05 2016-03-30 Twist Bioscience Corp De novo synthesized gene libraries
CA2975852A1 (en) 2015-02-04 2016-08-11 Twist Bioscience Corporation Methods and devices for de novo oligonucleic acid assembly
US9981239B2 (en) 2015-04-21 2018-05-29 Twist Bioscience Corporation Devices and methods for oligonucleic acid library synthesis
EA201890763A1 (ru) 2015-09-18 2018-08-31 Твист Байосайенс Корпорейшн Библиотеки вариантных олигонуклеиновых кислот и их синтез
KR102794025B1 (ko) 2015-09-22 2025-04-09 트위스트 바이오사이언스 코포레이션 핵산 합성을 위한 가요성 기판
WO2017095958A1 (en) 2015-12-01 2017-06-08 Twist Bioscience Corporation Functionalized surfaces and preparation thereof
GB201604458D0 (en) 2016-03-16 2016-04-27 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against cancers
CR20220248A (es) 2016-03-16 2022-07-18 Immatics Biotechnologies Gmbh Células t transfectadas y receptores de células t de utilidad en inmunoterapias contra el cáncer
WO2018038772A1 (en) 2016-08-22 2018-03-01 Twist Bioscience Corporation De novo synthesized nucleic acid libraries
EP3516528B1 (en) 2016-09-21 2025-10-15 Atlas Data Storage, Inc. Nucleic acid based data storage
MD3551221T2 (ro) 2016-12-08 2022-04-30 Immatics Biotechnologies Gmbh Noi receptori de celule T și imunoterapie cu utilizarea acestora
DE102016123847B3 (de) 2016-12-08 2018-04-05 Immatics Biotechnologies Gmbh Neue T-Zellrezeptoren und deren Verwendung in Immuntherapie
GB2573069A (en) * 2016-12-16 2019-10-23 Twist Bioscience Corp Variant libraries of the immunological synapse and synthesis thereof
JP2020508661A (ja) 2017-02-22 2020-03-26 ツイスト バイオサイエンス コーポレーション 核酸ベースのデータ保存
CN110913865A (zh) 2017-03-15 2020-03-24 特韦斯特生物科学公司 免疫突触的变体文库及其合成
SG10202107869QA (en) * 2017-04-10 2021-08-30 Immatics Biotechnologies Gmbh Peptides and combination thereof for use in the immunotherapy against cancers
SG11201912057RA (en) 2017-06-12 2020-01-30 Twist Bioscience Corp Methods for seamless nucleic acid assembly
WO2018231864A1 (en) 2017-06-12 2018-12-20 Twist Bioscience Corporation Methods for seamless nucleic acid assembly
CN111566125A (zh) 2017-09-11 2020-08-21 特韦斯特生物科学公司 Gpcr结合蛋白及其合成
EP3691662A4 (en) * 2017-10-06 2021-05-12 The University of Chicago Screening of t lymphocytes for cancer-specific antigens
US12178787B2 (en) 2017-10-12 2024-12-31 Board Of Regents, The University Of Texas System T cell receptors for immunotherapy
KR102637566B1 (ko) 2017-10-20 2024-02-16 트위스트 바이오사이언스 코포레이션 폴리뉴클레오타이드 합성을 위한 가열된 나노웰
CN112041438B (zh) 2018-01-04 2025-05-23 特韦斯特生物科学公司 基于dna的数字信息存储
GB201803750D0 (en) 2018-03-08 2018-04-25 Immunocore Ltd Method
DE102018108612A1 (de) 2018-03-21 2019-09-26 Immatics US, Inc. Verfahren zur erhöhung der persistenz von adoptiv infundierten t-zellen
WO2019196088A1 (en) 2018-04-13 2019-10-17 Syz Cell Therapy Co. Methods of obtaining tumor-specific t cell receptors
CN118957038A (zh) 2018-05-18 2024-11-15 特韦斯特生物科学公司 用于核酸杂交的多核苷酸、试剂和方法
US20210317184A1 (en) * 2018-09-05 2021-10-14 GlaxoSmithKline Intellectual Property Devolopment Limited T cell modification
JP7528058B2 (ja) * 2018-09-14 2024-08-05 イマティクス バイオテクノロジーズ ゲーエムベーハー Ｔｃｒリガンドの高スループットペプチド－ｍｈｃ親和性スクリーニングのための方法
DE102018122546B3 (de) 2018-09-14 2019-12-05 Immatics Biotechnologies Gmbh Verfahren zum Hochdurchsatz-Peptid-MHC-Affinitätsscreening für TCR-Liganden
CA3124980A1 (en) 2018-12-26 2020-07-02 Twist Bioscience Corporation Highly accurate de novo polynucleotide synthesis
WO2020176680A1 (en) 2019-02-26 2020-09-03 Twist Bioscience Corporation Variant nucleic acid libraries for antibody optimization
JP2022521551A (ja) 2019-02-26 2022-04-08 ツイスト バイオサイエンス コーポレーション Ｇｌｐ１受容体の変異体核酸ライブラリ
US20200297768A1 (en) 2019-03-19 2020-09-24 Immatics US, Inc. Cd28 t cell cultures, compositions, and methods of using thereof
DE102019108125B4 (de) 2019-03-28 2022-02-03 Immatics US, Inc. Cd28 t-zellkulturen, zusammensetzungen und verfahren zu deren verwendung
EP3714941A1 (en) 2019-03-27 2020-09-30 Medigene Immunotherapies GmbH Mage-a4 tcrs
CN111748029B (zh) * 2019-03-29 2022-12-13 苏州蓝马医疗技术有限公司 一种针对egfr l858r基因突变的特异性t细胞受体及其应用
CN111748028A (zh) * 2019-03-29 2020-10-09 天津亨佳生物科技发展有限公司 一种针对egfr l858r基因突变的特异性t细胞受体及其应用
EA202193074A1 (ru) * 2019-05-08 2022-03-21 Медиджин Иммунотерапис Гмбх Сконструированные т-клетки
AU2020283500A1 (en) 2019-05-27 2022-01-27 Immatics US, Inc. Viral vectors and their use in adoptive cellular therapy
MX2021015946A (es) * 2019-06-18 2022-04-18 Regeneron Pharma Receptores de linfocitos t de mage-a4 y métodos de uso de estos.
CA3144054A1 (en) * 2019-06-20 2020-12-24 Memorial Sloan-Kettering Cancer Center T cell receptors targeting pik3ca mutations and uses thereof
WO2020257612A1 (en) 2019-06-21 2020-12-24 Twist Bioscience Corporation Barcode-based nucleic acid sequence assembly
CN110357953B (zh) * 2019-07-17 2022-05-03 深圳市因诺转化医学研究院 识别人巨细胞病毒pp65抗原的TCR
EP4004033A4 (en) * 2019-07-30 2023-12-06 University Health Network MHC CLASS II MOLECULES AND METHODS OF USE
US20210032370A1 (en) 2019-08-02 2021-02-04 Immatics Biotechnologies Gmbh Recruiting agent further binding an mhc molecule
DE102019121007A1 (de) 2019-08-02 2021-02-04 Immatics Biotechnologies Gmbh Antigenbindende Proteine, die spezifisch an MAGE-A binden
JP2022548783A (ja) 2019-09-23 2022-11-21 ツイスト バイオサイエンス コーポレーション 単一ドメイン抗体のバリアント核酸ライブラリー
WO2021061829A1 (en) 2019-09-23 2021-04-01 Twist Bioscience Corporation Variant nucleic acid libraries for crth2
CN115279389A (zh) * 2020-01-06 2022-11-01 纪念斯隆-凯特琳癌症中心 新型显性负性Fas多肽、包含其的细胞及其用途
AU2021225817A1 (en) 2020-02-24 2022-10-20 Immatics US, Inc. Methods for expanding T cells for the treatment of cancer and related malignancies
DE102020111571A1 (de) 2020-03-11 2021-09-16 Immatics US, Inc. Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren
US20220056411A1 (en) * 2020-08-21 2022-02-24 Immatics US, Inc. Methods for isolating cd8+ selected t cells
KR102587454B1 (ko) * 2020-10-07 2023-10-11 주식회사 다안바이오테라퓨틱스 T 세포 수용체, t 세포 수용체를 포함하는 면역 세포 및 이를 이용하는 방법
KR20230135589A (ko) 2020-12-31 2023-09-25 이매틱스 유에스 인코포레이티드 Cd8 폴리펩타이드, 조성물 및 이의 사용 방법
DE102021100038A1 (de) 2020-12-31 2022-06-30 Immatics US, Inc. Modifizierte cd8-polypeptide, zusammensetzungen und verfahren zu deren verwendung
CN115975003B (zh) * 2021-03-09 2024-01-26 科士华(南京)生物技术有限公司 Tcr、多肽、表达载体、宿主细胞、药物组合物和tcr获得方法
WO2022225836A1 (en) * 2021-04-21 2022-10-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Hla class i-restricted t cell receptors against ras with q61k mutation
KR20240004937A (ko) 2021-05-05 2024-01-11 이매틱스 바이오테크놀로지스 게엠베하 Bma031 항원 결합 폴리펩타이드
CN113337514B (zh) * 2021-08-05 2021-10-29 卡瑞济(北京)生命科技有限公司 Tcr表达构建体以及其制备方法和用途
TW202332765A (zh) 2021-09-20 2023-08-16 美商英麥提克斯股份有限公司 用於ｔ細胞療法之ｔ細胞群體的單核球耗盡
CN113773378B (zh) * 2021-10-14 2023-11-03 深圳大学总医院 T细胞受体及其应用
CA3236646A1 (en) * 2021-11-03 2023-05-11 Ji Wang Novel anti-l1cam antibody
WO2023081461A1 (en) 2021-11-08 2023-05-11 Immatics US, Inc. Methods for generating cell spheroids
EP4448108A1 (en) 2021-11-08 2024-10-23 Immatics Biotechnologies GmbH Adoptive cell therapy combination treatment and compositions thereof
CA3247927A1 (en) 2022-01-14 2023-07-20 Tune Therapeutics Inc Compositions, systems and methods for programming T-lymphocyte phenotypes by targeted gene repression
WO2023137471A1 (en) 2022-01-14 2023-07-20 Tune Therapeutics, Inc. Compositions, systems, and methods for programming t cell phenotypes through targeted gene activation
WO2023148494A1 (en) * 2022-02-03 2023-08-10 University College Cardiff Consultants Limited Novel t-cell receptor
WO2023183758A2 (en) * 2022-03-19 2023-09-28 Regeneron Pharmaceuticals, Inc. Multispecific molecules targeting cd3 and mage-a4 and uses thereof
JP2025515604A (ja) 2022-04-28 2025-05-20 イマティクス ユーエス，アイエヌシー． ドミナントネガティブＴＧＦβ受容体ポリペプチド、ＣＤ８ポリペプチド、細胞、組成物、およびその使用方法
US20230348548A1 (en) 2022-04-28 2023-11-02 Immatics US, Inc. Membrane-bound il-15, cd8 polypeptides, cells, compositions, and methods of using thereof
US20240066127A1 (en) 2022-04-28 2024-02-29 Immatics US, Inc. Il-12 polypeptides, il-15 polypeptides, il-18 polypeptides, cd8 polypeptides, compositions, and methods of using thereof
WO2023215825A1 (en) 2022-05-05 2023-11-09 Immatics US, Inc. Methods for improving t cell efficacy
CN119698428A (zh) * 2022-06-24 2025-03-25 安进公司 Magea4特异性t细胞受体
WO2024036166A1 (en) * 2022-08-08 2024-02-15 The University Of North Carolina At Chapel Hill Bioorthogonal t cell receptor molecules and methods of making and using the same
JP2025531268A (ja) 2022-09-19 2025-09-19 チューン セラピューティクス インコーポレイテッド Ｔ細胞機能を調節するための組成物、システム、および方法
WO2025029835A1 (en) 2023-07-31 2025-02-06 Tune Therapeutics, Inc. Compositions and methods for modulating il-2 gene expression
WO2025029840A1 (en) 2023-07-31 2025-02-06 Tune Therapeutics, Inc. Compositions and methods for multiplexed activation and repression of t cell gene expression
US20250134931A1 (en) 2023-11-01 2025-05-01 Immatics US, Inc. Membrane-bound il-15, cd8 polypeptides, cells, compositions, and methods of using thereof
WO2025233420A1 (en) 2024-05-07 2025-11-13 Immatics Biotechnologies Gmbh Use of anti-cancer molecules

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007032255A1 (ja) 2005-09-13 2007-03-22 Mie University Ｔ細胞レセプター及び該レセプターをコードする核酸
WO2008053579A1 (en) 2006-10-30 2008-05-08 National University Corporation Hokkaido University Antigenic polypeptide usable as therapeutic agent for malignant neoplasm

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2618835T3 (pl) 2010-09-20 2017-12-29 Biontech Cell & Gene Therapies Gmbh Swoiste względem antygenu receptory komórek T i epitopy dla komórek T
MY160662A (en) * 2011-04-01 2017-03-15 Memorial Sloan Kettering Cancer Center T cell receptor-like antibodies specific for a wt1 peptide presented by hla-a2
JP6041314B2 (ja) * 2011-08-31 2016-12-07 国立大学法人三重大学 がん治療用ワクチン製剤
WO2013057596A1 (en) 2011-10-21 2013-04-25 Atena Srl Anatomic cushion accumulator for thermal treatment with heat or cold
GB2508414A (en) * 2012-11-30 2014-06-04 Max Delbrueck Centrum Tumour specific T cell receptors (TCRs)
EP3572510B1 (en) * 2013-11-21 2022-09-21 Repertoire Genesis Incorporation T cell receptor and b cell receptor repertoire analysis system, and use of same in treatment and diagnosis
US10202640B2 (en) * 2014-05-07 2019-02-12 The Board Of Trustees Of The Leland Stanford Junior University Single cell analysis of T cells using high-throughput multiplex amplification and deep sequencing

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007032255A1 (ja) 2005-09-13 2007-03-22 Mie University Ｔ細胞レセプター及び該レセプターをコードする核酸
JP2013126415A (ja) 2005-09-13 2013-06-27 Mie Univ Ｔ細胞レセプター及び該レセプターをコードする核酸
WO2008053579A1 (en) 2006-10-30 2008-05-08 National University Corporation Hokkaido University Antigenic polypeptide usable as therapeutic agent for malignant neoplasm
US20100034841A1 (en) 2006-10-30 2010-02-11 National University Corporation Hokkaido University Antigenic polypeptide usable as therapeutic agent for malignant neoplasm

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Clin. Devel. Immunol., Vol. 2010, Article ID567594(2010.)

Also Published As

Publication number Publication date
AU2021204753A1 (en) 2021-08-05
SG11201807868VA (en) 2018-10-30
KR102259109B1 (ko) 2021-06-01
MA43720A (fr) 2018-11-28
MA43330A1 (fr) 2019-07-31
AU2017235467B2 (en) 2021-04-08
US20170267738A1 (en) 2017-09-21
US10538573B2 (en) 2020-01-21
KR20210063486A (ko) 2021-06-01
EP3430030B1 (en) 2023-12-20
TWI764886B (zh) 2022-05-21
CA3017502A1 (en) 2017-09-21
TW201736396A (zh) 2017-10-16
EP3430030A1 (en) 2019-01-23
JP2019511222A (ja) 2019-04-25
CR20180492A (es) 2019-01-31
MY189042A (en) 2022-01-21
MA43330B1 (fr) 2020-06-30
JP7340127B2 (ja) 2023-09-07
CN108884136B (zh) 2023-03-17
KR20180118783A (ko) 2018-10-31
WO2017158103A1 (en) 2017-09-21
MX2018011225A (es) 2018-11-22
CN108884136A (zh) 2018-11-23
EA201892021A1 (ru) 2019-02-28
AU2017235467A1 (en) 2018-11-01
GB201604492D0 (en) 2016-04-27

Similar Documents

Publication Publication Date Title
KR102457504B1 (ko) 암에 대한 면역요법에서의 사용을 위하여 형질주입된 t 세포 및 t 세포 수용체
US20240279308A1 (en) Transfected t-cells and t-cell receptors for use in immunotherapy against cancers
KR102266721B1 (ko) 암에 대한 면역요법에서의 사용을 위하여 형질주입된 t 세포 및 t 세포 수용체
US20230321208A1 (en) Transfected t-cells and t-cell receptors for use in immunotherapy against cancers
EA043021B1 (ru) Трансфицированные t-клетки и t-клеточные рецепторы для применения в иммунотерапии раковых заболеваний
HK40003640A (en) Transfected t-cells and t-cell receptors for use in immunotherapy against cancers
HK40003640B (en) Transfected t-cells and t-cell receptors for use in immunotherapy against cancers

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20210525

Application number text: 1020187029016

Filing date: 20181008

PG1501 Laying open of application
AMND Amendment
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20210611

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20210625

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20211230

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20210625

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20211230

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20210823

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20210611

Comment text: Amendment to Specification, etc.

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20220414

Patent event code: PE09021S01D

AMND Amendment
PX0701 Decision of registration after re-examination

Patent event date: 20220719

Comment text: Decision to Grant Registration

Patent event code: PX07013S01D

Patent event date: 20220614

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20220304

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20211230

Comment text: Decision to Refuse Application

Patent event code: PX07011S01I

Patent event date: 20210823

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20210611

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

X701 Decision to grant (after re-examination)
GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20221018

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20221018

End annual number: 3

Start annual number: 1

PG1601 Publication of registration